Tofranil is a brand name for the tricyclic antidepressant imipramine. It is prescribed to relieve symptoms of major depressive disorder. The drug functions by inhibiting the reuptake of norepinephrine and serotonin in the central nervous system. This action increases the concentration of these neurotransmitters available for signaling. The enhanced neurotransmitter availability is thought to improve mood regulation over time. Clinical effects typically emerge after several weeks of consistent use. The medication is administered orally in tablet form under medical supervision.

Tofranil is the brand name for imipramine, a tricyclic antidepressant used primarily to treat major depressive disorder and certain anxiety disorders. Its pharmacological action involves the inhibition of norepinephrine and serotonin reuptake, thereby increasing the availability of these neurotransmitters in the brain. By blocking the serotonin transporter and norepinephrine transporter, Tofranil enhances mood regulation and reduces symptoms of depression. The medication also exhibits antagonistic activity at several histamine h1 and cholinergic receptors, contributing to its sedative and side-effect profile. Over time, chronic use leads to receptor down-regulation and adaptive changes that help sustain therapeutic benefit despite ongoing blockade of reuptake mechanisms. These combined effects produce a gradual improvement in depressive symptoms through modulation of monoaminergic pathways.

The most common side effects of many medications include mild fatigue and occasional headache. Some individuals may experience temporary gastrointestinal discomfort such as nausea or indigestion. Dizziness and lightheadedness are frequently reported during the initial adjustment period. Skin reactions like mild rash or itching can occur without serious consequences. Sleep disturbances such as difficulty falling asleep or altered sleep patterns are often noted. Changes in taste or mild metallic sensation may be observed during treatment. Most of these effects are transient and typically resolve without intervention.

Headaches are frequently reported as a common side effect of many treatments. Nausea often occurs particularly when a medication is taken on an empty stomach. Fatigue can be experienced as the body adjusts to new therapy. Dizziness may appear, especially during the first few days of treatment. Dry mouth is noted in many patients as the medication affects salivary glands. Mild skin rash sometimes develops but usually resolves without intervention. Occasional sweating can increase, reflecting changes in circulation. Transient changes in taste perception are observed in some individuals.